Uncategorized

Iveric Bio to Present Top-line Results for Avacincaptad Pegol from Phase 3 GATHER2 Clinical Trial in Geographic Atrophy at AAO 2022 Annual Meeting

by Business Wire • 2022/09/27 • 0 Comments

PARSIPPANY, N.J.--(BUSINESS WIRE)--Iveric Bio will present top-line efficacy and safety results from GATHER2, the Company’s second Phase 3 clinical trial of Zimura, at AAO 2022.

Full Story →

← Aura Biosciences to Present Ongoing Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (AU-011) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at AAO 2022

Versant Health Names Darrin Furtado Vice President of Underwriting →

Post navigation